Stem Cell Transplant Clinical Trials

139 recruitingLast updated: June 18, 2026

There are 139 actively recruiting stem cell transplant clinical trials across 27 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Boston, Massachusetts, United States, Beijing, Beijing Municipality, China, Suzhou, Jiangsu, China. Updated daily from ClinicalTrials.gov.


Stem Cell Transplant Trials at a Glance

139 actively recruiting trials for stem cell transplant are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 2 with 48 trials, with the heaviest enrollment activity in Boston, Beijing, and Suzhou. Lead sponsors running stem cell transplant studies include The First Affiliated Hospital of Soochow University, Peking University People's Hospital, and Children's Hospital Medical Center, Cincinnati.

Browse stem cell transplant trials by phase

Treatments under study

About Stem Cell Transplant Clinical Trials

Looking for clinical trials for Stem Cell Transplant? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Stem Cell Transplant trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Stem Cell Transplant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 139 trials

Recruiting
Phase 2

Ivosidenib as Post-HSCT Maintenance for AML

Acute Myeloid Leukemia (AML)IDH1 MutationHematopoietic Stem Cell Transplant (HSCT)
Massachusetts General Hospital75 enrolled5 locationsNCT06707493
Recruiting
Phase 1Phase 2

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Hematopoietic Stem Cell TransplantationPeripheral Blood Stem Cell Transplantation
National Cancer Institute (NCI)260 enrolled2 locationsNCT05436418
Recruiting
Not Applicable

Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant

Hematopoietic Stem Cell Transplantation
National Cancer Institute (NCI)222 enrolled2 locationsNCT05605574
Recruiting

ATLG Levels in Autologous HSCT for Multiple Sclerosis

Multiple SclerosisAutologous Hematopoietic Stem Cell TransplantATLG
Ciceri Fabio20 enrolled1 locationNCT07635693
Recruiting

Long-Term Follow-up of People Undergoing Hematopoietic Stem Cell Transplantation

Hematopoietic Stem Cell TransplantationTissue Donors
National Cancer Institute (NCI)2,000 enrolled1 locationNCT03000244
Recruiting
Early Phase 1

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

LymphomaLeukemiaCAR-T Cell Therapy+3 more
University of Arizona200 enrolled1 locationNCT06643221
Recruiting
Early Phase 1

Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Mari Dallas20 enrolled1 locationNCT03378102
Recruiting
Phase 1Phase 2

Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

Sickle Cell DiseaseGraft FailureHematopoetic Stem Cell Transplant+2 more
Arkansas Children's Hospital Research Institute24 enrolled4 locationsNCT07252050
Recruiting
Not Applicable

Aromatherapy Inhaler Use for HSCT Distress

Cancer DistressAromatherapyCancer Coping+1 more
Stanford University50 enrolled1 locationNCT05302583
Recruiting
Phase 4

Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationCytomegalovirus Infections+1 more
WeiShi120 enrolled12 locationsNCT07569653
Recruiting
Phase 3

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Phase 2Phase 3

VABu Conditioning in Elderly AML HSCT

Acute Myeloid Leukemia (AML)Allogeneic Hematopoietic Stem Cell Transplantation Recipient
The First Affiliated Hospital of Soochow University20 enrolled1 locationNCT07583888
Recruiting
Phase 2

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting
Phase 2

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Hematopoietic Stem Cell TransplantationImmunodeficiency
National Cancer Institute (NCI)54 enrolled1 locationNCT05027945
Recruiting
Phase 2

Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Acute Graft Versus Host DiseaseGraft-Versus-Host DiseaseALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology42 enrolled1 locationNCT07572669
Recruiting

Longitudinal Cohort Study on Invasive Fungal Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Invasive Fungal DiseaseAllogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Peking University People's Hospital6,000 enrolled1 locationNCT07569055
Recruiting
Not Applicable

Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation

Hematopoietic Stem Cell Transplant
University of Michigan Rogel Cancer Center10 enrolled1 locationNCT05945121
Recruiting

Oral, Chemosensory and Trigeminal Functions in Allo-HSCT

Hematopoietic Stem Cell Transplantation
University of Oslo70 enrolled1 locationNCT06003660
Recruiting
Phase 2

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Sickle Cell DiseaseStem Cell Transplant ComplicationsPure Red Cell Aplasia+1 more
University of Calgary12 enrolled1 locationNCT03214354
Recruiting

A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT

Acute LeukemiaMenin InhibitorsPost Hematopoietic Stem Cell Transplantation+4 more
The First Affiliated Hospital of Soochow University20 enrolled1 locationNCT07559695